{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:42:41Z","timestamp":1790775761671,"version":"4.1.0"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,9,19]],"date-time":"2020-09-19T00:00:00Z","timestamp":1600473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,9,19]],"date-time":"2020-09-19T00:00:00Z","timestamp":1600473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s13555-020-00447-y","type":"journal-article","created":{"date-parts":[[2020,9,19]],"date-time":"2020-09-19T09:02:44Z","timestamp":1600506164000},"page":"1185-1198","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":74,"title":["Vitiligo, From Physiopathology to Emerging Treatments: A Review"],"prefix":"10.1007","volume":"10","author":[{"given":"Laure","family":"Migayron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Boniface","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1139-0908","authenticated-orcid":false,"given":"Julien","family":"Seneschal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,19]]},"reference":[{"key":"447_CR1","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.det.2016.11.002","volume":"35","author":"N Elbuluk","year":"2017","unstructured":"Elbuluk N, Ezzedine K. Quality of life, burden of disease, co-morbidities, and systemic effects in vitiligo patients. Dermatol Clin. 2017;35:117\u201328.","journal-title":"Dermatol Clin"},{"key":"447_CR2","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s12016-017-8622-7","volume":"54","author":"K Boniface","year":"2018","unstructured":"Boniface K, Seneschal J, Picardo M, Ta\u00efeb A. Vitiligo: focus on clinical aspects, immunopathogenesis, and therapy. Clin Rev Allergy Immunol. 2018;54:52\u201367.","journal-title":"Clin Rev Allergy Immunol"},{"key":"447_CR3","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12955-020-1278-7","volume":"18","author":"N Hamidizadeh","year":"2020","unstructured":"Hamidizadeh N, Ranjbar S, Ghanizadeh A, Parvizi MM, Jafari P, Handjani F. Evaluating prevalence of depression, anxiety and hopelessness in patients with vitiligo on an Iranian population. Health Qual Life Outcomes. 2020;18:20. https:\/\/doi.org\/10.1186\/s12955-020-1278-7.","journal-title":"Health Qual Life Outcomes"},{"key":"447_CR4","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/bjd.15199","volume":"177","author":"YC Lai","year":"2017","unstructured":"Lai YC, Yew YW, Kennedy C, Schwartz RA. Vitiligo and depression: a systematic review and meta-analysis of observational studies. Br J Dermatol. 2017;177:708\u201318.","journal-title":"Br J Dermatol"},{"key":"447_CR5","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.det.2016.11.013","volume":"35","author":"RA Spritz","year":"2017","unstructured":"Spritz RA, Andersen GHL. Genetics of vitiligo. Dermatol Clin. 2017;35:245\u201355.","journal-title":"Dermatol Clin"},{"key":"447_CR6","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/sj.jidsp.5640189","volume":"4","author":"KU Schallreuter","year":"1999","unstructured":"Schallreuter KU, Moore J, Wood JM, et al. In vivo and in vitro evidence for hydrogen peroxide (H2O2) accumulation in the epidermis of patients with vitiligo and its successful removal by a UVB-activated pseudocatalase. J Investig Dermatol Symp Proc. 1999;4:91\u20136.","journal-title":"J Investig Dermatol Symp Proc"},{"key":"447_CR7","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.12659\/MSM.914898","volume":"25","author":"Y Wang","year":"2019","unstructured":"Wang Y, Li S, Li C. Perspectives of new advances in the pathogenesis of vitiligo: from oxidative stress to autoimmunity. Med Sci Monit. 2019;25:1017\u201323.","journal-title":"Med Sci Monit"},{"issue":"10","key":"447_CR8","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1016\/j.jid.2019.03.1148","volume":"139","author":"T Cui","year":"2019","unstructured":"Cui T, Zhang W, Li S, et al. Oxidative stress-induced HMGB1 release from melanocytes: a paracrine mechanism underlying the cutaneous inflammation in vitiligo. J Invest Dermatol. 2019;139:2174\u201384.e.","journal-title":"J Invest Dermatol"},{"key":"447_CR9","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/jid.2013.268","volume":"134","author":"Y Zhang","year":"2014","unstructured":"Zhang Y, Liu L, Jin L, et al. Oxidative stress-induced calreticulin expression and translocation: new insights into the destruction of melanocytes. J Investig Dermatol. 2014;134:183\u201391.","journal-title":"J Investig Dermatol"},{"key":"447_CR10","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.anndiagpath.2012.11.005","volume":"17","author":"AG Abdou","year":"2013","unstructured":"Abdou AG, Maraee AH, Reyad W. Immunohistochemical expression of heat shock protein 70 in vitiligo. Ann Diagn Pathol. 2013;17:245\u20139.","journal-title":"Ann Diagn Pathol"},{"key":"447_CR11","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1038\/jid.2008.45","volume":"128","author":"CJ Denman","year":"2008","unstructured":"Denman CJ, McCracken J, Hariharan V, et al. HSP70i accelerates depigmentation in a mouse model of autoimmune vitiligo. J Invest Dermatol. 2008;128:2041\u20138.","journal-title":"J Invest Dermatol"},{"key":"447_CR12","doi-asserted-by":"publisher","first-page":"174ra28","DOI":"10.1126\/scitranslmed.3005127","volume":"5","author":"JA Mosenson","year":"2013","unstructured":"Mosenson JA, Zloza A, Nieland JD,  et al. Mutant HSP70 reverses autoimmune depigmentation in vitiligo. Sci Transl Med. 2013;5:174ra28. https:\/\/doi.org\/10.1126\/scitranslmed.3005127.","journal-title":"Sci Transl Med."},{"key":"447_CR13","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1755-148X.2011.00916.x","volume":"25","author":"JA Mosenson","year":"2012","unstructured":"Mosenson JA, Zloza A, Klarquist J, Barfuss AJ, Guevara-Patino JA, Le Poole IC. HSP70i is a critical component of the immune response leading to vitiligo. Pigment Cell Melanoma Res. 2012;25:88\u201398.","journal-title":"Pigment Cell Melanoma Res"},{"key":"447_CR14","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1016\/j.jid.2018.06.186","volume":"138","author":"SW Henning","year":"2018","unstructured":"Henning SW, Fernandez MF, Mahon JP, et al. HSP70iQ435A-encoding DNA repigments vitiligo lesions in sinclair swine. J Investig Dermatol. 2018;138:2531\u20139.","journal-title":"J Investig Dermatol"},{"key":"447_CR15","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1080\/14728222.2018.1439924","volume":"22","author":"U Andersson","year":"2018","unstructured":"Andersson U, Yang H, Harris H. Extracellular HMGB1 as a therapeutic target in inflammatory diseases. Expert Opin Ther Targets. 2018;22:263\u201377.","journal-title":"Expert Opin Ther Targets"},{"key":"447_CR16","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.phrs.2016.06.031","volume":"111","author":"E Venereau","year":"2016","unstructured":"Venereau E, De Leo F, Mezzapelle R, Careccia G, Musco G, Bianchi ME. HMGB1 as biomarker and drug target. Pharmacol Res. 2016;111:534\u201344.","journal-title":"Pharmacol Res"},{"key":"447_CR17","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1111\/bjd.15550","volume":"177","author":"C Jacquemin","year":"2017","unstructured":"Jacquemin C, Rambert J, Guillet S, et al. Heat shock protein 70 potentiates interferon alpha production by plasmacytoid dendritic cells: relevance for cutaneous lupus and vitiligo pathogenesis. Br J Dermatol. 2017;177:1367\u201375.","journal-title":"Br J Dermatol"},{"key":"447_CR18","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.jid.2016.09.021","volume":"137","author":"Y Jin","year":"2017","unstructured":"Jin Y, Andersen GHL, Santorico SA, Spritz RA. Multiple functional variants of IFIH1, a gene involved in triggering innate immune responses, protect against vitiligo. J Investig Dermatol. 2017;137:522\u20134.","journal-title":"J Investig Dermatol"},{"key":"447_CR19","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/s41419-020-2665-z","volume":"11","author":"T Zhuang","year":"2020","unstructured":"Zhuang T, Yi X, Chen J, et al. Intracellular virus sensor MDA5 exacerbates vitiligo by inducing the secretion of chemokines in keratinocytes under virus invasion. Cell Death Dis. 2020;11:453. https:\/\/doi.org\/10.1038\/s41419-020-2665-z.","journal-title":"Cell Death Dis"},{"key":"447_CR20","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/pcmr.12219","volume":"27","author":"A Bertolotti","year":"2014","unstructured":"Bertolotti A, Boniface K, Vergier B, et al. Type I interferon signature in the initiation of the immune response in vitiligo. Pigment Cell Melanoma Res. 2014;27:398\u2013407.","journal-title":"Pigment Cell Melanoma Res"},{"key":"447_CR21","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1177\/0961203317700486","volume":"26","author":"E Bahloul","year":"2017","unstructured":"Bahloul E, Jallouli M, Garbaa S, et al. Hydroxychloroquine-induced hyperpigmentation in systemic diseases: prevalence, clinical features and risk factors: a cross-sectional study of 41 cases. Lupus. 2017;26:1304\u20138.","journal-title":"Lupus"},{"key":"447_CR22","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/1756-185X.12442","volume":"18","author":"K Joo","year":"2015","unstructured":"Joo K, Park W, Kwon SR, Lim MJ, Jung K-H. Improvement of vitiligo in a patient with rheumatoid arthritis after hydroxychloroquine treatment. Int J Rheum Dis. 2015;18:679\u201380.","journal-title":"Int J Rheum Dis"},{"key":"447_CR23","doi-asserted-by":"crossref","first-page":"464","DOI":"10.15252\/emmm.201404719","volume":"7","author":"A Pellerin","year":"2015","unstructured":"Pellerin A, Otero K, Czerkowicz JM, et al. Anti-BDCA2 monoclonal antibody inhibits plasmacytoid dendritic cell activation through Fc-dependent and Fc-independent mechanisms. EMBO Mol Med. 2015;7:464\u201376.","journal-title":"EMBO Mol Med"},{"key":"447_CR24","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1172\/JCI124466","volume":"129","author":"R Furie","year":"2019","unstructured":"Furie R, Werth VP, Merola JF, et al. Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus. J Clin Investig. 2019;129:1359\u201371.","journal-title":"J Clin Investig"},{"key":"447_CR25","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1136\/annrheumdis-2015-208562","volume":"75","author":"M Khamashta","year":"2016","unstructured":"Khamashta M, Merrill JT, Werth VP, et al. Sifalimumab, an anti-interferon-\u03b1 monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016;75:1909\u201316.","journal-title":"Ann Rheum Dis"},{"key":"447_CR26","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.39962","volume":"69","author":"R Furie","year":"2017","unstructured":"Furie R, Khamashta M, Merrill JT, et al. Anifrolumab, an anti-interferon-\u03b1 receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol. 2017;69:376\u201386.","journal-title":"Arthritis Rheumatol"},{"key":"447_CR27","doi-asserted-by":"publisher","first-page":"e107020","DOI":"10.1371\/journal.pone.0107020","volume":"9","author":"NC Laddha","year":"2014","unstructured":"Laddha NC, Dwivedi M, Mansuri MS, et al. Association of neuropeptide Y (NPY), interleukin-1B (IL1B) genetic variants and correlation of IL1B transcript levels with vitiligo susceptibility. PLoS ONE. 2014;9:e107020. https:\/\/doi.org\/10.1371\/journal.pone.0107020.","journal-title":"PLoS ONE"},{"key":"447_CR28","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/bjd.12691","volume":"170","author":"J Marie","year":"2014","unstructured":"Marie J, Kovacs D, Pain C, et al. Inflammasome activation and vitiligo\/nonsegmental vitiligo progression. Br J Dermatol. 2014;170:816\u201323.","journal-title":"Br J Dermatol"},{"key":"447_CR29","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1600-065X.2011.01042.x","volume":"243","author":"M Lamkanfi","year":"2011","unstructured":"Lamkanfi M, Vande Walle L, Kanneganti T-D. Deregulated inflammasome signaling in disease. Immunol Rev. 2011;243:163\u201373.","journal-title":"Immunol Rev"},{"key":"447_CR30","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jaad.2006.09.004","volume":"56","author":"E Nicolaidou","year":"2007","unstructured":"Nicolaidou E, Antoniou C, Stratigos AJ, Stefanaki C, Katsambas AD. Efficacy, predictors of response, and long-term follow-up in patients with vitiligo treated with narrowband UVB phototherapy. J Am Acad Dermatol. 2007;56:274\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"447_CR31","doi-asserted-by":"publisher","unstructured":"Richmond JM, Strassner JP, Zapata L, et al. Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo. Sci Transl Med. 2018;10(450):eaam7710. https:\/\/doi.org\/10.1126\/scitranslmed.aam7710.","DOI":"10.1126\/scitranslmed.aam7710"},{"key":"447_CR32","doi-asserted-by":"crossref","unstructured":"Khalil S, Bardawil T, Kurban M, Abbas O. Tissue-resident memory T cells in the skin. Inflamm Res. 2020;69(3):245\u201354.","DOI":"10.1007\/s00011-020-01320-6"},{"key":"447_CR33","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41423-019-0359-1","volume":"17","author":"SC Sasson","year":"2020","unstructured":"Sasson SC, Gordon CL, Christo SN, Klenerman P, Mackay LK. Local heroes or villains: tissue-resident memory T cells in human health and disease. Cell Mol Immunol. 2020;17:113\u201322.","journal-title":"Cell Mol Immunol"},{"key":"447_CR34","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/s41577-019-0162-3","volume":"19","author":"AW Ho","year":"2019","unstructured":"Ho AW, Kupper TS. T cells and the skin: from protective immunity to inflammatory skin disorders. Nat Rev Immunol. 2019;19:490\u2013502.","journal-title":"Nat Rev Immunol"},{"key":"447_CR35","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.3390\/ijms21103552","volume":"21","author":"A Fr\u0105czek","year":"2020","unstructured":"Fr\u0105czek A, Owczarczyk-Saczonek A, Placek W. The role of TRM cells in the pathogenesis of vitiligo-a review of the current state-of-the-art. Int J Mol Sci. 2020;21:3552.\nhttps:\/\/doi.org\/10.3390\/ijms21103552.","journal-title":"Int J Mol Sci."},{"key":"447_CR36","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.3389\/fimmu.2018.01347","volume":"9","author":"Y Pan","year":"2018","unstructured":"Pan Y, Kupper TS. Metabolic reprogramming and longevity of tissue-resident memory T cells. Front Immunol. 2018;9:1347. https:\/\/doi.org\/10.3389\/fimmu.2018.01347.","journal-title":"Front Immunol"},{"key":"447_CR37","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nature21379","volume":"543","author":"Y Pan","year":"2017","unstructured":"Pan Y, Tian T, Park CO, et al. Survival of tissue-resident memory T cells requires exogenous lipid uptake and metabolism. Nature. 2017;543:252\u20136.","journal-title":"Nature"},{"key":"447_CR38","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jid.2017.08.038","volume":"138","author":"K Boniface","year":"2018","unstructured":"Boniface K, Jacquemin C, Darrigade A-S, et al. Vitiligo skin is imprinted with resident memory CD8 T cells expressing CXCR3. J Invest Dermatol. 2018;138:355\u201364.","journal-title":"J Invest Dermatol"},{"key":"447_CR39","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.autrev.2017.07.005","volume":"16","author":"R Speeckaert","year":"2017","unstructured":"Speeckaert R, Speeckaert M, De Schepper S, van Geel N. Biomarkers of disease activity in vitiligo: a systematic review. Autoimmun Rev. 2017;16:937\u201345.","journal-title":"Autoimmun Rev"},{"key":"447_CR40","doi-asserted-by":"publisher","first-page":"223ra23","DOI":"10.1126\/scitranslmed.3007811","volume":"6","author":"M Rashighi","year":"2014","unstructured":"Rashighi M, Agarwal P, Richmond JM, et al. CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo. Sci Transl Med. 2014;6:223ra23. https:\/\/doi.org\/10.1126\/scitranslmed.3007811.","journal-title":"Sci Transl Med."},{"key":"447_CR41","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1001\/jamadermatol.2017.6401","volume":"154","author":"S Nguyen","year":"2018","unstructured":"Nguyen S, Chuah SY, Fontas E, et al. Atorvastatin in combination with narrowband UV-B in adult patients with active vitiligo: a randomized clinical trial. JAMA Dermatol. 2018;154:725\u20136.","journal-title":"JAMA Dermatol"},{"issue":"150\u2013151","key":"447_CR42","first-page":"e3","volume":"76","author":"SG Vanderweil","year":"2017","unstructured":"Vanderweil SG, Amano S, Ko W-C, et al. A double-blind, placebo-controlled, phase-II clinical trial to evaluate oral simvastatin as a treatment for vitiligo. J Am Acad Dermatol. 2017;76(150\u2013151):e3.","journal-title":"J Am Acad Dermatol"},{"key":"447_CR43","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.jid.2016.10.048","volume":"137","author":"JM Richmond","year":"2017","unstructured":"Richmond JM, Masterjohn E, Chu R, Tedstone J, Youd ME, Harris JE. CXCR3 depleting antibodies prevent and reverse vitiligo in mice. J Invest Dermatol. 2017;137:982\u20135.","journal-title":"J Invest Dermatol"},{"key":"447_CR44","doi-asserted-by":"crossref","unstructured":"Jacquemin C, Martins C, Lucchese F, et al. NKG2D defines a subset of skin effector memory CD8 T cells with proinflammatory functions in vitiligo. J Invest Dermatol. 2020;140(6):1143\u201353.e5.","DOI":"10.1016\/j.jid.2019.11.013"},{"key":"447_CR45","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.3390\/ijms1809199","volume":"18","author":"K Vadstrup","year":"2017","unstructured":"Vadstrup K, Bendtsen F. Anti-NKG2D mAb: a new treatment for Crohn\u2019s disease? Int J Mol Sci. 2017;18:1997. https:\/\/doi.org\/10.3390\/ijms1809199","journal-title":"Int J Mol Sci."},{"key":"447_CR46","doi-asserted-by":"publisher","unstructured":"Martins C, Darrigade A-S, Jacquemin C, et al. Phenotype and function of circulating memory T cells in human vitiligo. Br J Dermatol. 2020. https:\/\/doi.org\/10.1111\/bjd.18902.","DOI":"10.1111\/bjd.18902"},{"key":"447_CR47","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/j.jaci.2018.11.031","volume":"143","author":"T Czarnowicki","year":"2019","unstructured":"Czarnowicki T, He H, Leonard A, et al. Blood endotyping distinguishes the profile of vitiligo from that of other inflammatory and autoimmune skin diseases. J Allergy Clin Immunol. 2019;143:2095\u2013107.","journal-title":"J Allergy Clin Immunol"},{"key":"447_CR48","doi-asserted-by":"publisher","first-page":"tr8","DOI":"10.1126\/stke.2602004tr8","volume":"2004","author":"CM Horvath","year":"2004","unstructured":"Horvath CM. The Jak-STAT pathway stimulated by interferon gamma. Sci STKE. 2004;2004:tr8. https:\/\/doi.org\/10.1126\/stke.2602004tr8.","journal-title":"Sci STKE."},{"key":"447_CR49","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/B978-0-12-407707-2.00005-9","volume":"119","author":"J Li","year":"2013","unstructured":"Li J, Yin Q, Wu H. Structural basis of signal transduction in the TNF receptor superfamily. Adv Immunol. 2013;119:135\u201353.","journal-title":"Adv Immunol"},{"key":"447_CR50","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/1346-8138.14004","volume":"45","author":"L Yang","year":"2018","unstructured":"Yang L, Yang S, Lei J, et al. Role of chemokines and the corresponding receptors in vitiligo: a pilot study. J Dermatol. 2018;45:31\u20138.","journal-title":"J Dermatol"},{"key":"447_CR51","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jid.2016.09.016","volume":"137","author":"JM Richmond","year":"2017","unstructured":"Richmond JM, Bangari DS, Essien KI, et al. Keratinocyte-derived chemokines orchestrate T-cell positioning in the epidermis during vitiligo and may serve as biomarkers of disease. J Invest Dermatol. 2017;137:350\u20138.","journal-title":"J Invest Dermatol"},{"key":"447_CR52","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1073\/pnas.1304988111","volume":"111","author":"VT Natarajan","year":"2014","unstructured":"Natarajan VT, Ganju P, Singh A, et al. IFN-\u03b3 signaling maintains skin pigmentation homeostasis through regulation of melanosome maturation. Proc Natl Acad Sci USA. 2014;111:2301\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"447_CR53","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/nchembio.1548","volume":"10","author":"VT Natarajan","year":"2014","unstructured":"Natarajan VT, Ganju P, Ramkumar A, Grover R, Gokhale RS. Multifaceted pathways protect human skin from UV radiation. Nat Chem Biol. 2014;10:542\u201351.","journal-title":"Nat Chem Biol"},{"key":"447_CR54","doi-asserted-by":"publisher","unstructured":"Boukhedouni N, Martins C, Darrigade A-S, et al. Type-1 cytokines regulate MMP-9 production and E-cadherin disruption to promote melanocyte loss in vitiligo. JCI Insight. 2020;5. https:\/\/doi.org\/10.1172\/jci.insight.133772.","DOI":"10.1172\/jci.insight.133772"},{"key":"447_CR55","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.autrev.2016.01.004","volume":"15","author":"RK Singh","year":"2016","unstructured":"Singh RK, Lee KM, Vujkovic-Cvijin I, et al. The role of IL-17 in vitiligo: a review. Autoimmun Rev. 2016;15:397\u2013404.","journal-title":"Autoimmun Rev"},{"key":"447_CR56","first-page":"835","volume":"17","author":"C Pincelli","year":"2018","unstructured":"Pincelli C, Schafer PH, French LE, Augustin M, Krueger JG. Mechanisms underlying the clinical effects of apremilast for psoriasis. J Drugs Dermatol. 2018;17:835\u201340.","journal-title":"J Drugs Dermatol"},{"key":"447_CR57","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/j.jaad.2017.11.056","volume":"78","author":"R Zebda","year":"2018","unstructured":"Zebda R, Paller AS. Phosphodiesterase 4 inhibitors. J Am Acad Dermatol. 2018;78:S43\u201352.","journal-title":"J Am Acad Dermatol"},{"key":"447_CR58","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1101\/gad.1937710","volume":"24","author":"M Khaled","year":"2010","unstructured":"Khaled M, Levy C, Fisher DE. Control of melanocyte differentiation by a MITF-PDE4D3 homeostatic circuit. Genes Dev. 2010;24:2276\u201381.","journal-title":"Genes Dev"},{"key":"447_CR59","doi-asserted-by":"publisher","first-page":"2386234","DOI":"10.1155\/2017\/2386234","volume":"2017","author":"SB Huff","year":"2017","unstructured":"Huff SB, Gottwald LD. Repigmentation of tenacious vitiligo on apremilast. Case Rep Dermatol Med. 2017;2017:2386234. https:\/\/doi.org\/10.1155\/2017\/2386234.","journal-title":"Case Rep Dermatol Med"},{"key":"447_CR60","doi-asserted-by":"crossref","unstructured":"Khemis A, Fontas E, Moulin S, Montaudi\u00e9 H, Lacour J-P, Passeron T. Apremilast in combination with narrowband UVB in the treatment of vitiligo: a 52-week monocentric prospective randomized placebo-controlled study. J Invest Dermatol. 2020; 140(8):1533\u201337.e2.","DOI":"10.1016\/j.jid.2019.11.031"},{"key":"447_CR61","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/bjd.14016","volume":"173","author":"KC Webb","year":"2015","unstructured":"Webb KC, Tung R, Winterfield LS, et al. Tumour necrosis factor-\u03b1 inhibition can stabilize disease in progressive vitiligo. Br J Dermatol. 2015;173:641\u201350.","journal-title":"Br J Dermatol"},{"key":"447_CR62","first-page":"534","volume":"11","author":"KM Alghamdi","year":"2012","unstructured":"Alghamdi KM, Khurrum H, Taieb A, Ezzedine K. Treatment of generalized vitiligo with anti-TNF-\u03b1 agents. J Drugs Dermatol. 2012;11:534\u20139.","journal-title":"J Drugs Dermatol"},{"key":"447_CR63","doi-asserted-by":"publisher","first-page":"e000239","DOI":"10.1136\/rmdopen-2015-000239","volume":"2","author":"\u00c9 Toussirot","year":"2016","unstructured":"Toussirot \u00c9, Aubin F. Paradoxical reactions under TNF-\u03b1 blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview. RMD Open. 2016;2:e000239. https:\/\/doi.org\/10.1136\/rmdopen-2015-000239.","journal-title":"RMD Open"},{"key":"447_CR64","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/jdv.13759","volume":"31","author":"L M\u00e9ry-Bossard","year":"2017","unstructured":"M\u00e9ry-Bossard L, Bagny K, Chaby G, et al. New-onset vitiligo and progression of pre-existing vitiligo during treatment with biological agents in chronic inflammatory diseases. J Eur Acad Dermatol Venereol. 2017;31:181\u20136.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"447_CR65","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.jid.2017.11.012","volume":"138","author":"JM Bae","year":"2018","unstructured":"Bae JM, Kim M, Lee HH, et al. Increased risk of vitiligo following anti-tumor necrosis factor therapy: a 10-year population-based cohort study. J Investg Dermatol. 2018;138:768\u201374.","journal-title":"J Invest Dermatol"},{"key":"447_CR66","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1038\/jid.2009.32","volume":"129","author":"JG van den Boorn","year":"2009","unstructured":"van den Boorn JG, Konijnenberg D, Dellemijn TAM, et al. Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol. 2009;129:2220\u201332.","journal-title":"J Invest Dermatol"},{"key":"447_CR67","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/pcmr.12789","volume":"32","author":"R Speeckaert","year":"2019","unstructured":"Speeckaert R, Mylle S, van Geel N. IL-17A is not a treatment target in progressive vitiligo. Pigment Cell Melanoma Res. 2019;32:842\u20137.","journal-title":"Pigment Cell Melanoma Res"},{"key":"447_CR68","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/bjd.18606","volume":"182","author":"P Mobasher","year":"2020","unstructured":"Mobasher P, Guerra R, Li SJ, Frangos J, Ganesan AK, Huang V. Open-label pilot study of tofacitinib 2% for the treatment of refractory vitiligo. Br J Dermatol. 2020;182:1047\u20139.","journal-title":"Br J Dermatol"},{"key":"447_CR69","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jaad.2019.04.032","volume":"81","author":"J McKesey","year":"2019","unstructured":"McKesey J, Pandya AG. A pilot study of 2% tofacitinib cream with narrowband ultraviolet B for the treatment of facial vitiligo. J Am Acad Dermatol. 2019;81:646\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"447_CR70","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1001\/jamadermatol.2017.5778","volume":"154","author":"SR Kim","year":"2018","unstructured":"Kim SR, Heaton H, Liu LY, King BA. Rapid repigmentation of vitiligo using tofacitinib plus low-dose, narrowband UV-B phototherapy. JAMA Dermatol. 2018;154:370\u20131.","journal-title":"JAMA Dermatol"},{"key":"447_CR71","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/ced.13290","volume":"42","author":"M Vu","year":"2017","unstructured":"Vu M, Heyes C, Robertson SJ, Varigos GA, Ross G. Oral tofacitinib: a promising treatment in atopic dermatitis, alopecia areata and vitiligo. Clin Exp Dermatol. 2017;42:942\u20134.","journal-title":"Clin Exp Dermatol"},{"key":"447_CR72","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamadermatol.2015.1520","volume":"151","author":"BG Craiglow","year":"2015","unstructured":"Craiglow BG, King BA. Tofacitinib citrate for the treatment of vitiligo: a pathogenesis-directed therapy. JAMA Dermatol. 2015;151:1110\u201312.","journal-title":"JAMA Dermatol"},{"key":"447_CR73","doi-asserted-by":"crossref","first-page":"1205.e1","DOI":"10.1016\/j.jaad.2018.02.023","volume":"78","author":"D Joshipura","year":"2018","unstructured":"Joshipura D, Alomran A, Zancanaro P, Rosmarin D. Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: a 32-week open-label extension study with optional narrow-band ultraviolet B. J Am Acad Dermatol. 2018;78:1205.e1\u20137.e1.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"447_CR74","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jaad.2017.02.049","volume":"76","author":"B Rothstein","year":"2017","unstructured":"Rothstein B, Joshipura D, Saraiya A, et al. Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib. J Am Acad Dermatol. 2017;76(6):1054-60.e1.","journal-title":"J Am Acad Dermatol"},{"key":"447_CR75","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jaad.2015.09.073","volume":"74","author":"JE Harris","year":"2016","unstructured":"Harris JE, Rashighi M, Nguyen N, et al. Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA). J Am Acad Dermatol. 2016;74:370\u20131.","journal-title":"J Am Acad Dermatol"},{"key":"447_CR76","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0140-6736(20)30609-7","volume":"396","author":"D Rosmarin","year":"2020","unstructured":"Rosmarin D, Pandya AG, Lebwohl M, et al. Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial. Lancet. 2020;396:110\u201320.","journal-title":"Lancet"},{"key":"447_CR77","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jgg.2011.05.005","volume":"38","author":"RA Spritz","year":"2011","unstructured":"Spritz RA. Recent progress in the genetics of generalized vitiligo. J Genet Genom. 2011;38:271\u20138.","journal-title":"J Genet Genom"},{"key":"447_CR78","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.autrev.2014.10.002","volume":"14","author":"M Dwivedi","year":"2015","unstructured":"Dwivedi M, Kemp EH, Laddha NC, Mansuri MS, Weetman AP, Begum R. Regulatory T cells in vitiligo: implications for pathogenesis and therapeutics. Autoimmun Rev. 2015;14:49\u201356.","journal-title":"Autoimmun Rev"},{"key":"447_CR79","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/jid.2015.26","volume":"135","author":"JM Eby","year":"2015","unstructured":"Eby JM, Kang H-K, Tully ST, et al. CCL22 to activate treg migration and suppress depigmentation in vitiligo. J Invest Dermatol. 2015;135:1574\u201380.","journal-title":"J Invest Dermatol"},{"key":"447_CR80","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.4049\/jimmunol.1900733","volume":"203","author":"M Tahvildari","year":"2019","unstructured":"Tahvildari M, Dana R. Low-dose IL-2 therapy in transplantation, autoimmunity, and inflammatory diseases. J Immunol. 2019;203:2749\u201355.","journal-title":"J Immunol"},{"key":"447_CR81","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1001\/jamadermatol.2014.504","volume":"150","author":"E Castela","year":"2014","unstructured":"Castela E, Le Duff F, Butori C, et al. Effects of low-dose recombinant interleukin 2 to promote T-regulatory cells in alopecia areata. JAMA Dermatol. 2014;150:748\u201351.","journal-title":"JAMA Dermatol"},{"key":"447_CR82","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1111\/1523-1747.ep12492612","volume":"97","author":"KU Schallreuter","year":"1991","unstructured":"Schallreuter KU, Wood JM, Berger J. Low catalase levels in the epidermis of patients with vitiligo. J Invest Dermatol. 1991;97:1081\u20135.","journal-title":"J Invest Dermatol"},{"key":"447_CR83","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1111\/jdv.14792","volume":"32","author":"R Speeckaert","year":"2018","unstructured":"Speeckaert R, Dugardin J, Lambert J,et al. Critical appraisal of the oxidative stress pathway in vitiligo: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2018;32:1089\u201398.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"447_CR84","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.2147\/DDDT.S239912","volume":"14","author":"SR Mercuri","year":"2020","unstructured":"Mercuri SR, Vollono L, Paolino G. The usefulness of platelet-rich plasma (PRP) for the treatment of vitiligo: state of the art and review. Drug Des Dev Ther. 2020;14:1749\u201355.","journal-title":"Drug Des Dev Ther"},{"key":"447_CR85","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/jidsymp.1997.17","volume":"2","author":"TA Luger","year":"1997","unstructured":"Luger TA, Scholzen T, Grabbe S. The role of alpha-melanocyte-stimulating hormone in cutaneous biology. J Investig Dermatol Symp Proc. 1997;2:87\u201393.","journal-title":"J Investig Dermatol Symp Proc"},{"key":"447_CR86","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1749-6632.1999.tb08679.x","volume":"885","author":"AJ Thody","year":"1999","unstructured":"Thody AJ. alpha-MSH and the regulation of melanocyte function. Ann N Y Acad Sci. 1999;885:217\u201329.","journal-title":"Ann N Y Acad Sci"},{"key":"447_CR87","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.peptides.2005.01.027","volume":"27","author":"PC Eves","year":"2006","unstructured":"Eves PC, MacNeil S, Haycock JW. Alpha-melanocyte stimulating hormone, inflammation and human melanoma. Peptides. 2006;27:444\u201352.","journal-title":"Peptides"},{"key":"447_CR88","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/jamadermatol.2014.1875","volume":"151","author":"HW Lim","year":"2015","unstructured":"Lim HW, Grimes PE, Agbai O, et al. Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial. JAMA Dermatol. 2015;151:42\u201350.","journal-title":"JAMA Dermatol"},{"key":"447_CR89","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1001\/2013.jamadermatol.386","volume":"149","author":"PE Grimes","year":"2013","unstructured":"Grimes PE, Hamzavi I, Lebwohl M, Ortonne JP, Lim HW. The efficacy of afamelanotide and narrowband UV-B phototherapy for repigmentation of vitiligo. JAMA Dermatol. 2013;149:68\u201373.","journal-title":"JAMA Dermatol"},{"key":"447_CR90","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1038\/jid.2015.335","volume":"135","author":"C Regazzetti","year":"2015","unstructured":"Regazzetti C, Joly F, Marty C, et al. Transcriptional analysis of vitiligo skin reveals the alteration of WNT pathway: a promising target for repigmenting vitiligo patients. J Invest Dermatol. 2015;135:3105\u201314.","journal-title":"J Invest Dermatol"},{"key":"447_CR91","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/jid.2014.527","volume":"135","author":"M Cavali\u00e9","year":"2015","unstructured":"Cavali\u00e9 M, Ezzedine K, Fontas E, et al. Maintenance therapy of adult vitiligo with 01% tacrolimus ointment: a randomized, double blind, placebo-controlled study. J Invest Dermatol. 2015;135:970\u20134.","journal-title":"J Invest Dermatol."}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-020-00447-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-020-00447-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-020-00447-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,19]],"date-time":"2021-09-19T00:25:40Z","timestamp":1632011140000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-020-00447-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,19]]},"references-count":91,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["447"],"URL":"https:\/\/doi.org\/10.1007\/s13555-020-00447-y","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,19]]},"assertion":[{"value":"31 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}